Reports Q2 revenue $699.3M, consensus $690M. Adjusted EBITDA was $110 million an increase of $43 million, and adjusted EBITDA margin was 16 percent, an increase of 500 basis points. “Our second quarter results show the dedication of Exact Sciences’ world-class team and the power of our unique platform,” said Kevin Conroy, chairman and CEO. “We delivered answers to more patients and healthcare professionals than ever before, achieved record revenue and profitability, and advanced each of our key pipeline programs. Momentum continues to build, fueling our purpose to help eradicate cancer.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- EXAS Upcoming Earnings Report: What to Expect?
- Bernstein says Medicare panel discussion negative for Exact Sciences
- CMS proposal would be positive for Guardant Health, says Craig-Hallum
- Exact Sciences price target lowered to $72 from $80 at Evercore ISI
- Dynatrace initiated, U.S. Bancorp downgraded: Wall Street’s top analyst calls